We noted in a cohort of patients with malignant carcinoid tumors that as many as 19% of patients receiving long-term treatment with IFN-α eventually manifested an autoimmune disease (14), including systemic lupus erythematosus (SLE). The gene discussed is IFNA1; the disease is systemic lupus erythematosus.